16 May 2016
From 18 to 20 May 2016, the nine institutes of the Asia-Pacific region will meet at the Institut Pasteur of Shanghai/Chinese Academy of Science. They will review their current institutional partnerships and initiate new ones. Discussions will help to develop specific research, public health as well as regional educational programs.
Different sessions will address the following topics: outbreaks and emergencies, antimicrobial resistance, cancers induced by viruses, industrial valorization, funding mechanisms and training & teaching strategies. The discussions ahead of the working groups meetings will be open to public.
The Institut Pasteur International Network includes 33 institutes around the world, located in 5 regional centers (i.e. Europe, Asia-Pacific, Americas, Africa, Maghreb-Iran). Each of these groups ensure a regional coverage on research, surveillance and control of infectious diseases, with close synergy between regions creating a common space to share technologies, methods, expertise resources and data throughout the 5 continents.
Please find the program of the meeting here.
The Institut Pasteur International Network Asia-Pacific Regional meeting will gather invited speakers, Institut Pasteur and Institut Pasteur International Network representatives and members of the nine institutes in the Asia-Pacific region:
- Institut Pasteur of Shanghai/Chinese Academy of Sciences
- Hong Kong University Pasteur Research Pole
- National Institute of Hygiene and Epidemiology, Hanoi, Vietnam
- Institut Pasteur in Nha Trang, Vietnam
- Institut Pasteur in Ho Chi Minh City, Vietnam
- Institut Pasteur in Cambodia
- Institut Pasteur in New Caledonia
- Institut Pasteur in Laos
- Institut Pasteur in Korea
12 May 2016
While the Zika outbreak is currently one of the hot topic in the fields of virology and public health, another arbovirus stays close to international attention: Dengue virus. The world first dengue vaccine (Dengvaxia® (CYD-TDV), developed by Sanofi Pasteur) has been registered in Mexico, the Philippines, Brazil and El Salvador. In April 2016, the WHO Advisory Group of Experts (SAGE) on immunization emitted its first recommendation after reviewing the vaccine: introduce it "only in geographic settings with high endemicity". WHO has announced that the organization will publish a more detailed report in July 2016 to specify its position and its recommendations regarding the vaccine.
Dr. Philippe Dussart, Institut Pasteur in Cambodia. © Healthwise
Dengvaxia and dengue vaccine development is just one of the subjects addressed by Dr. Philippe Dussart, Head of the Virology Unit at the Institut Pasteur in Cambodia in an interview called "The Dengue Peril" by the Cambodian magazine Healthwise Digest (Vol. 2 No.12 March 2016). Dr. Dussart comes back to the increase of dengue cases in Cambodia, the disease prevention, the time needed to develop vaccines, the absence of treatment drug.
Read the interview here.
10 May 2016
The Symposium on Transmission and Control of Respiratory Pathogens, jointly organized by the WHO Collaborating Centre for Infectious Disease Epidemiology and Control at the School of Public Health of the University of Hong Kong and the RGC Theme-based Research Scheme on Viral, Host and Environmental Determinants of Influenza Virus Transmission and Pathogenesis will take place on Tuesday 14 June 2016, from 14.00 to 18.00.
Venue: Cheung Kung Hai Conference Centre William MW Mong Block, 21 Sassoon Road, Pokfulam, Hong Kong
Professor Zhong Nan-Shan
Dr Werner E. Bischoff
Dr Samira Mubareka
Professor David Hui Shu-Cheong
Professor Malik Peiris
Professor Benjamin J. Cowling
Dr Joseph Wu Tsz-Kei
Dr Yen Hui-Ling
28 Apr 2016
MRC Technology and Institut Pasteur of Shanghai, Chinese Academy of Sciences collaborate on antibody drug development
On March 7th, MRC Technology (Medical Research Council Technology transfer charity, UK) and Institut Pasteur of Shanghai, Chinese Academy of Sciences - IPS-CAS signed a collaboration agreement to develop new therapeutic antibodies from research originating in China.
Monoclonal antibody-based drugs have been established as one of the most successful therapeutic strategies for the treatment of infectious diseases, cancers and autoimmune diseases. “The promise of immune check-point antibodies and broadly neutralizing antibodies against pathogens brings a boom in research and research development across the world, which makes this collaboration all the more significant and important”, said Professor Sun Bing, the Director of IPS-MRCT Joint Centre for Therapeutic Antibodies.
Read more on IPS-CAS website: here
28 Apr 2016
3rd Edition of the Centre Pasteur of Cameroon’s Scientific Days, 28-30 September 2016, Centre Pasteur of Cameroon, Yaounde, Cameroon
Theme: "Emerging and Re-emerging Infections: New findings, Threats and Control Strategies"
In the globalized world, emerging and re-emerging infectious diseases represent major public health threats in coming decades. The 1960s was filled with great optimism: with advances in medicine and the development of adequate preventive measures, we observed a significant decline in infectious diseases. This decline was further apparent by the eradication of some diseases such as smallpox in 1977. However, in the last three decades, we have observed a surge in several emerging and often fatal infections such as HIV/AIDS, respiratory infections (severe acute respiratory syndrome (SARS) and the Middle East Respiratory Syndrome associated to Coronavirus (MERS-CoV)), viral haemorrhagic fevers (Ebola and Lassa viruses), arboviruses (West Nile and Zika viruses), and other zoonotic infection. Conversely, certain infectious diseases including chikungunya and tuberculosis that were already in decline are re-emerging. Multiple factors could favour the emergence of infectious diseases but most cases are related to the evolution of the pathogen, the vectors as well as changes in the host’s environment (climatic, socio-economic and cultural) that affect the ecosystem.
The aim of the 3rd Centre Pasteur of Cameroon’s Scientific Days is to bring together experts from different disciplines (Virology, Bacteriology, Mycology and Parasitology) working on human and animal health, environmentalists, anthropologists, and policy makers with focused discussions on emerging and re-emerging infections. Discussions will be organized under five sub-themes, and each will be approached in a multidisciplinary manner. The purpose is to sensitize stakeholders towards a "One Health" approach in the fight against emerging and re-emerging infections.
1. Diagnostic Tools
2. Epidemiology and surveillance
3. Vectors and reservoirs
4. Control Strategies
5. Socio-Anthropological aspects
The symposium is opened to all scientists.Opportunities will be given to companies to display their products in dedicated booths around the conference center.
Abstracts will be accepted for both oral or poster presentation, and may be submitted in English or French.
The abstract submission deadline is May 30, 2016, by e-mail at: email@example.com
The deadline for pre-registration is 1 July 2016.
26 Apr 2016
Over 600 researchers and experts are gathering at the Institut Pasteur in Paris for the International Zika Summit 2016 (25-26 April). The speed of the Zika virus propagation requires open collaborations between researchers, the public health community and the public. This meeting aims at providing a venue for open such discussions. The meeting is sponsored by the Institut Pasteur, the Bill and Melinda Gates Foundation and the Wellcome Trust, with organizational support from WHO, REACTing, Aviesan, the European Commission, USCDC and ISARIC.
Press conference, International Zika Summit 2016 © Institut Pasteur
Zika virus is now present in over 34 countries in Latin America and the Caribbean affecting over 1.5 million people. On Zika virus potential to enter Europe, researchers at the Institut Pasteur's Arboviruses and Insect Vectors Unit led by Anna-Bella Failloux worked with Portuguese researchers (Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa) to assess the vector competence, or virus transmission potential, of four mosquito populations: two populations of Aedes aegypti from Madeira and two populations of Aedes albopictus from southern France. The scientists infected female mosquitoes with Zika virus belonging to the Asian genotype equivalent to that currently circulating in Brazil. The results show that Ae. aegypti transmits the virus more effectively than Ae. albopictus. In Ae. aegypti, the virus only takes 9 days to complete a full cycle and infect the insect's salivary glands, ready to be inoculated into a new host through a bite. In contrast, Ae. albopictus completes the same cycle in 14 days which significantly limits transmission. It therefore appears that tiger mosquitoes in southern France and probably continental Europe are less capable of transmitting Zika virus locally which seems to support a hypothetical scenario whereby transmission is limited to regions in which Ae. aegypti is present.
Read the full news on the Institut Pasteur website: here.
You can read the preprint study on bioRxiv:
Zika virus, a new threat for Europe? Henri JUPILLE, Goncalo SEIXAS, Laurence MOUSSON, Carla SOUSA, Anna-Bella FAILLOUX doi: http://dx.doi.org/10.1101/048454